Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus–Infected Donors to Noninfected Recipients
Christine M. Durand(Johns Hopkins University), Niraj M. Desai(Johns Hopkins University), Darin Ostrander(Johns Hopkins University), Dorry L. Segev(Johns Hopkins Medicine), Mary G. Bowring(Johns Hopkins University), Mark Sulkowski(Johns Hopkins University), Jeremy Sugarman(Johns Hopkins University), Diane Brown(Johns Hopkins University), Michael A. Chattergoon(Johns Hopkins University), Ashraf Reyad(Johns Hopkins University), Nichole Bair(Johns Hopkins University), Russell Wesson(Johns Hopkins University), Fizza Naqvi(Johns Hopkins University), Guido Massaccesi(Johns Hopkins University)
Cited by 295
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|847